Galapagos/€GLPG

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Galapagos

Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.

Ticker

€GLPG
Sector

Primary listing

AEX

Employees

558

Galapagos Metrics

BasicAdvanced
€2.1B
-
-€4.32
0.03
-

What the Analysts think about Galapagos

Analyst ratings (Buy, Hold, Sell) for Galapagos stock.

Bulls say / Bears say

On May 13, 2025, Galapagos’ Board decided to revisit its previously planned mid-2025 spin-off, founding Galapagos Cell Therapeutics and engaging Morgan Stanley as advisor to assess all strategic options. This reflects agile management and disciplined capital allocation aimed at maximizing shareholder value (Reuters).
Galapagos treated its first U.S. patient in the ATALANTA-1 Phase 1/2 trial for GLPG5101, targeting relapsed/refractory non-Hodgkin lymphoma, with mantle cell lymphoma chosen as its primary registrational indication. Pivotal development is expected to start in 2026, with initial approval projected for 2028, signaling promising near-term pipeline catalysts (Galapagos Press Release).
The launch of Galapagos Cell Therapeutics as an independent unit for all cell therapy activities, along with the appointments of Henry Gosebruch as CEO and Jérôme Contamine as Board Chair, tightens organizational focus on the key growth area of cell therapies (Galapagos Half-Year Update).
For the six months ended June 30, 2025, Galapagos’ operating loss rose sharply to €215.7 million from €71.3 million in the prior year, primarily due to €131.6 million in strategic reorganization and separation costs. This highlights ongoing unprofitability and elevated cash burn risk (Reuters).
Galapagos’ move to halt all small-molecule R&D programs—including its Phase 3–ready TYK2 inhibitor GLPG3667—means topline data will not be available until the first half of 2026. This postpones value creation and potential partnership milestones tied to these assets (Galapagos Annual Report).
The near-concurrent departures of CEO Paul Stoffels (retiring) and CFO/COO Thad Huston (leaving August 1, 2025) increase execution and governance risks during a crucial period of strategic reviews and pipeline progress (Galapagos Press Release).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.

Galapagos Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Galapagos Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €GLPG

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs